SBShane A. Bobart

Shane A. Bobart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shane A. Bobart has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serologic Discrimination of Histologic Classes in Lupus Nephritis

    by Adnan Fatfat, Ishaan Batish, Abhinav Sharma, Dory Arevalo Salazar, Sam T. Albadri, Vikas Majithia, Nabeel Aslam, Shane A. Bobart

    Background: Anti-dsDNA positivity and hypocomplementemia are markers of active lupus nephritis (LN), but their ability to discriminate between histologic phenotypes remains underexplored, particularly for mixed proliferative/membranous LN (mixed LN). We compared baseline serologic markers across proliferative LN, membranous LN, and mixed LN, and evaluated their discriminative performance for histologic class. Methods: We conducted a retrospective cross-sectional study of 132 patients with biopsy-proven LN, categorized according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification into proliferative LN (class III/IV), membranous LN (class V), and mixed LN (class III/IV+V). Baseline anti-dsDNA and complements C3 and C4 were compared across groups. Receiver operating characteristic (ROC) analysis assessed the ability of individual and combined markers to discriminate between histologic classes. Kidney outcomes at 12 months were explored in a secondary cohort (n=88). Results: Of 132 patients, 57 had proliferative LN, 32 had membranous LN, and 43 had mixed LN. Anti-dsDNA was significantly higher, and C3 and C4 significantly lower, in proliferative and mixed LN compared to membranous LN ( P <0.05 for all), while proliferative and mixed LN did not differ significantly. On ROC analysis, individual markers achieved AUCs of 0.68-0.71 for distinguishing proliferative or mixed LN from membranous LN, with combined models yielding AUCs of 0.73. However, discrimination between proliferative and mixed LN was poor (combined AUC 0.62). At 12 months, kidney outcomes were comparable across groups. Conclusions: Mixed LN exhibits a serologic profile resembling proliferative LN, both sharing elevated anti-dsDNA and low complement levels, but distinct from membranous LN. Serology could inform suspicion for LN class but cannot replace kidney biopsy.

  • Masked IgG-kappa dominant proliferative glomerulonephritis as monoclonal gammopathy of renal significance with marked renal response to daratumumab-based therapy

    by Abhinav Sharma, Ishaan Batish, Adnan Fatfat, Md Shahrier Amin, Sandhya Manohar, Ricardo Parrondo, Nabeel Aslam, Shane A Bobart

    Monoclonal gammopathy of renal significance (MGRS) encompasses renal lesions caused by nephrotoxic monoclonal immunoglobulins produced by small B-cell or plasma cell clones that do not meet criteria for overt hematologic malignancy. Diagnosis may be challenging when immune deposits are masked on routine immunofluorescence. We report a 63-year-old woman with hypertension, chronic kidney disease, peripheral neuropathy, venous thromboembolism, and progressive proteinuria who underwent kidney biopsy for worsening urinary abnormalities. Routine immunofluorescence on frozen tissue was negative; however, repeat immunofluorescence on protease-digested paraffin-embedded tissue demonstrated focal and segmental granular staining for IgG and kappa light chain with essentially negative lambda staining, consistent with proliferative glomerulonephritis with masked IgG-kappa dominant deposits. Congo red stain was negative. Bone marrow biopsy subsequently showed approximately 8% plasma cells with an abnormal kappa-excess plasma cell population, and serum immunofixation identified IgG-kappa monoclonal protein, supporting MGRS. Due to baseline peripheral neuropathy, bortezomib-based therapy was deferred, and the patient was treated with daratumumab, lenalidomide, and dexamethasone. Kidney function remained preserved, and proteinuria improved markedly from nephrotic-range level of 8.5–0.22 g/g. This case highlights the diagnostic importance of paraffin immunofluorescence when MGRS is suspected despite negative routine studies and illustrates that early clone-directed therapy can produce substantial renal response in masked monoclonal proliferative glomerulonephritis.

  • Open Access

    Successful Use of Obinutuzumab in Refractory Phospholipase A2 Receptor–Associated Membranous Nephropathy: A Case Report

    by Ishaan Batish, Abhinav Sharma, Adnan Fatfat, Ashwin P. Jaikishen, Agnes Fogo, Nabeel Aslam, Shane A. Bobart

  • Open Access

    Compass Rose

    by Shane A. Bobart, Nabeel Aslam

  • Technology-Enabled Remote Patient Monitoring and Education to Improve Kidney Transplant Knowledge, Access, and Post-Transplant Care: A Narrative Review

    by Solaf Al Awadhi, Mariam Ismail, Shane A. Bobart, Paula K. Shireman, David A. Axelrod, Amy D. Waterman

    Purpose of Review Given significant barriers to transplant access and suboptimal post-transplant outcomes, particularly for underserved populations, this review provides a summary of the studies assessing technology-enabled tools for remote patient monitoring (RPM) and education to improve kidney transplant knowledge, access, and care. Drawing on quantitative and qualitative research, we examine how digital health interventions enhance transplant knowledge, adherence, and long-term outcomes while providing recommendations for their effective design and integration into transplant care. Recent Findings Studies demonstrate that technology-enabled interventions, including mobile health applications and personalized educational platforms complemented by provider’s support, improve transplant knowledge, adherence to immunosuppressive therapy, and blood pressure management. Programs also incorporating socio-economic support have been effective in improving transplant knowledge and progression toward transplant among African American and Hispanic patients. Patients value features such as personalized reminders, user-friendly interfaces, and storytelling platforms. However, challenges such as privacy concerns, technology access, and usability remain. Ensuring a patient-centered, culturally, and socioeconomically sensitive approach—while integrating a holistic, multi-level framework that involves patients, caregivers, donors, and healthcare providers and addresses educational, clinical, mental, and social needs—can enhance engagement and health outcomes. Emerging interventions, including wearable biosensors, chatbot-assisted education, artificial intelligence for risk prediction, and remote patient-reported outcome platforms, are expanding transplant care possibilities but require further evaluation, scalability, and centralized integration. Summary Technology-enabled tools offer promising opportunities to address key challenges in kidney transplant care. Future research should focus on scaling, integrating, and optimizing these interventions within a Human Technology Co-Care model, combining digital innovation with provider engagement to ensure equitable, efficient, and patient-centered care.

  • Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis

    by Jing Miao, Jaleh Zand, Lisa Vaughan, Maria Jose Soler, Montserrat M Díaz Encarnación, Luis F Quintana, Andrew S Bomback, Charat Thongprayoon, Benjamin Wooden, Shane A Bobart, et al.

    Background: Membranous nephropathy (MN) associated with phospholipase A2 receptor (PLA2R) antibodies is the most common cause of nephrotic syndrome in non-diabetic adult patients. This study investigated the relationship between clinical phenotypes and renal outcomes in this population, emphasizing the potential for phenotype-based treatment stratification. Methods: We conducted a retrospective, multi-center cohort study of PLA2R-positive MN. Unsupervised cluster analysis grouped patients based on clinicopathological characteristics. Primary outcomes included complete or partial remission within 2 years of biopsy and end-stage kidney disease (ESKD) or death during follow-up. Results: Among 178 patients, three distinct clusters emerged (n = 89, 70, and 19). Within 2 years of biopsy, 102 patients (57%) achieved complete or partial remission. Cluster 1, characterized by the mildest disease markers, including the lowest body mass index, serum anti-PLA2R titer, serum creatinine, proteinuria, and triglycerides, had the highest remission rate of 72%, compared with 50% in cluster 2 and 54% in cluster 3. Cluster 2 had significantly lower remission compared to cluster 1 (HR 0.64, 95% CI 0.42–0.96, P = .03); results were similar in cluster 3, albeit not statistically significant (HR 0.50, 95% CI 0.23–1.09, P = .08). Elevated anti-PLA2R levels (>100 U/ml) and proteinuria (>8 g/24-hour) predicted reduced remission (HR 0.56, 95% CI 0.36–0.88, P = .01; HR 0.43, 95% CI 0.26–0.73, P = .002, respectively), while high high-density lipoprotein levels were protective (HR 1.01, 95% CI 1.00–1.02, P = .048). Overall, 21 patients (12%) developed ESKD or died. ESKD-free survival differed significantly across clusters (log-rank test P = .04). Conclusions: Unsupervised clustering identified distinct clinical phenotypes in PLA2R-positive MN, each associated with different renal prognoses. Phenotype-based risk stratification could enhance treatment precision, improve patient outcomes, and potentially reduce treatment-related adverse effects.


  • Open Access

    Development of a Natural Language Processing Model for Extracting Kidney Biopsy Pathology Diagnoses

    by Shane A. Bobart, Enshuo Hsu, Thomas Potter, Luan Truong, Amy Waterman, Stephen Jones, Tariq Shafi


  • Open Access

    The Clinical and Pathological Characteristics of Patients with Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits

    by Tariku T. Gudura, Hanny Sawaf, Randy Ogbenna, Ali Mehdi, Leal Herlitz, Surafel K. Gebreselassie, Shane A. Bobart

    Introduction: Proliferative glomerulonephritis with monoclonal immunoglobin (Ig) deposits (PGNMID) is a rare form of kidney disease associated with low monoclonal protein detection rates and poor renal outcomes. The lack of effective therapy is partly due to limited data and understanding of its pathogenesis. Methods: We conducted a retrospective analysis of 18 patients with PGNMID from the Cleveland Clinic Kidney Biopsy Epidemiology Project from January 2015 to March 2023. Results: PGNMID was more predominant among males (67%), and whites (78%), with median age of 60 years. Over 2/3rd of patients presented with hypertension, renal insufficiency, and hematuria, while 26% of patients had nephrotic syndrome. Mean serum creatinine and proteinuria at biopsy were 3.2 mg/dL and 4.3 g/g, respectively. A detectable monoclonal (M) protein was detected in 28% of cases; however, only 3 patients had underlying hematologic disorders (multiple myeloma, CLL, and B-cell lymphoma). An endocapillary hypercellularity/membranoproliferative pattern (72%), IgG/kappa (83%), and IgG3 (56%) were predominant findings on kidney pathology. Eight patients (44%) progressed to end-stage kidney disease (ESKD), with a median onset of 7.5 months after the initial kidney biopsy. While 6 patients achieved complete remission primarily with clone-directed therapy. Conclusion: Despite monoclonal protein deposition on kidney biopsy, 28% patients with PGNMID had a detectable monoclonal protein. Unlike other forms of paraproteinemic kidney diseases, renal outcomes for patients with PGNMID are poor, with 44% progressing to ESKD (median time 7.5 months) after kidney biopsy in our cohort. Clone-directed therapy to improve outcomes remains the mainstay of treatment, despite the absence of detectable clone in most cases. Thus, further investigation into the pathogenesis of PGNMID is warranted to guide future treatment discovery and clinical trials.


  • Open Access

    Double Trouble in the Basement! A Case of PLA2R-Associated Membranous Nephropathy with Atypical Anti-Glomerular Basement Membrane Disease

    by Renuka Tolani, Steffi Sathiyaraj, David Lyu, Luan Truong, Theresa Thurston, Ziad M. El-Zaatari, Ali R. Khan, Angelina Edwards, Shane A. Bobart

    Introduction: Concurrent atypical anti-glomerular basement membrane (anti-GBM) disease with membranous nephropathy is a rare occurrence. Compared to typical anti-GBM disease, atypical anti-GBM disease is often seronegative, with a mild disease presentation and course. We present a case of concomitant of PLA2R-associated membranous nephropathy and atypical anti-GBM disease in a patient with cholangiocarcinoma. Case Presentation: A 66-year-old male with type 2 diabetes, hypertension, hyperlipidemia, hepatitis C, cirrhosis, and cholangiocarcinoma presented with nephrotic range proteinuria and worsening bilateral lower extremity edema. Urine studies showed 3+ protein and 13 red blood cells per high power field and 24-h urine protein of 14 g (nephrotic range). Serum albumin was 2.1 g/dL and serum creatinine was 0.8 mg/dL (nephrotic syndrome). Serological work-up was negative for antinuclear antibody, anti-double stranded DNA antibody, anti-PLA2R, anti-neutrophil cytoplasmic antibody, rheumatoid factor, and anti-GBM. Complement (C3 and C4) levels were normal and no monoclonal gammopathy was detected. A kidney biopsy showed membranous nephropathy with typical light microscopic, immunofluorescence, and electron microscopic findings. In addition, there was atypical anti-GBM disease characterized by a non-circumferential cellular crescent in 1 out of 12 glomeruli 2–3+ linear staining for IgG along GBM. There was no tubular basement membrane staining for IgG and albumin staining was negative. The glomeruli demonstrated strong staining for PLA2R but were negative for THSD7A and NELL-1. The patient received rituximab infusion, dapagliflozin, and lisinopril, resulting in remission of proteinuria. Despite intense chemotherapy with cisplatin, gemcitabine, and immunotherapy, the patient’s cholangiocarcinoma progressed, and he transitioned to hospice care. Conclusion: For our patient, rituximab resulted in remission of proteinuria. The lack of temporal association with the malignancy is consistent with the biopsy findings of PLA2R-associated membranous nephropathy. While there is not an established guideline for atypical anti-GBM disease, our case demonstrates the utility of rituximab for the management of concurrent atypical anti-GBM disease with membranous nephropathy.

  • Open Access

    Kidney Biopsy Findings Among Patients With Diabetes in the Cleveland Clinic Kidney Biopsy Epidemiology Project

    by Alvin G. Kwon, Hanny Sawaf, Gilda Portalatin, Shruti Shettigar, Leal C. Herlitz, Tariq Shafi, Hong Liang, Adam Kabuka, Scott Cohen, Surafel K. Gebreselassie, et al.